Stoke is pioneering a new way to treat the underlying cause of severe genetic diseases by precisely upregulating protein expression. We develop antisense oligonucleotide medicines that increase gene expression to treat genetic epilepsies and other severe monogenic diseases, including genetic conditions affecting the central nervous system, eye, liver and kidney. We believe our proprietary technology platform, Targeted Augmentation of Nuclear Gene Output, or TANGO, will allow us to deliver disease-modifying therapies in a highly precise, durable and controlled manner. Source
No articles found.
Natera is a rapidly-growing diagnostics company with proprietary bioinformatics an...
Natera is a rapidly-growing diagnostics company...
Maternova, Inc. is the trusted resource for cutting edge medical innovations in ne...
Maternova, Inc. is the trusted resource for cut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solut...
Syneos HealthÂŽ (Nasdaq:SYNH) is the only fully...
Over a century ago in Melbourne, Australia, we made a promise to save lives and pr...
Over a century ago in Melbourne, Australia, we ...
Sanofi is dedicated to supporting people through their health challenges. We are a...
Sanofi is dedicated to supporting people throug...
Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company pursuing no...
Madrigal Pharmaceuticals is a clinical-stage bi...
Synlogic⢠is pioneering the development of a novel class of living Synthetic Bio...
Synlogic⢠is pioneering the development of a ...
Join the National Investor Network and get the latest information with your interests in mind.